EYLEA: Eylea wins approval in China for diabetic macular edema

Bayer (ETR:BAYN) said today that the Chinese State Food and Drug Administration has approved Eylea to treat patients who have visual impairment due to diabetic macular edema. It's the first indication for Eylea to be approved by the Chinese regulatory body. The injectable eye drug is sold by Regeneron (NSDQ:REGN) in the U.S. and has been approved [...]The post Eylea wins approval in China for diabetic macular edema appeared first on Drug Delivery Business.